Vertex Pharmaceuticals

Update in progress

VRTX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Vertex Pharmaceuticals is a U.S.-based biotechnology company focused on serious diseases, especially cystic fibrosis, sickle cell disease, transfusion dependent beta thalassemia, and acute pain. It markets CF medicines including TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, and is developing CASGEVY, JOURNAVX, VX-522, inaxaplin, VX-264, VX-670, and VX-407. Customers include specialty pharmacies, distributors, hospitals, and clinics. Founded 1989, Boston.

Company score

Sentiment: 2.17; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.05; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 1.16; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.54; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.48; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 1.32; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive